| Document |
Document Title |
|
WO/2020/071721A1 |
The present invention provides: a novel mixture which can improve the luminous efficiency, stability, and service life of an element; an organic electric element using same; and an electronic device thereof.
|
|
WO/2020/072695A1 |
3-Carbonylamino-8-aminoisoquinoline compounds of formula (I): variations thereof, and their use as inhibitors of HPK1 (hematopoietic kinase 1) are described. The compounds are useful in treating HPK1-dependent disorders and enhancing an ...
|
|
WO/2020/067657A1 |
The present invention relates to a composition for an organic optoelectronic element, an organic optoelectronic element and a display device, the composition comprising: a first compound for an organic optoelectronic element, represented...
|
|
WO/2020/064002A1 |
The present invention relates to a polysubstituted isoindoline compound as shown in general formula (I), and a preparation method, a pharmaceutical composition and the use thereof. In particular, the polysubstituted isoindoline compound ...
|
|
WO/2020/063760A1 |
Provided is a compound of formula I, their synthesis and their use for treating a SHP2 mediated disorder. More particularly, provided is a pharmaceutical composition comprising the said compound.
|
|
WO/2020/065048A1 |
The present invention is related to new compounds, pharmaceutical composition thereof and to their use for the treatment and/or prophylaxis of disorders or conditions related to Nicotinamide adenine dinucleotide phosphate oxidase (NADPH ...
|
|
WO/2020/065613A1 |
Fused compounds of Formula (I) and Formula (II), pharmaceutical compositions containing them, methods of making them, and methods of using them including methods for treating disease states, disorders, and conditions associated with MGL ...
|
|
WO/2020/067455A1 |
The objective of the present invention is to provide a compound which may be useful for preventing or treating constipation or the like. The present invention provides a compound represented by formula (I) [each symbol in the formula is ...
|
|
WO/2020/061046A1 |
Described herein are compounds that are somatostatin modulators, methods of making such compounds, pharmaceutical compositions and medicaments comprising such compounds, and methods of using such compounds in the treatment of conditions,...
|
|
WO/2020/060286A1 |
The present invention provides a novel heterocyclic compound and an organic light emitting device using same.
|
|
WO/2020/060268A1 |
The present invention relates to: a novel sulfonamide derivative with a fused pyrimidine skeleton, represented by chemical formula I; a solvate thereof or pharmaceutically acceptable salts thereof; and a pharmaceutical composition contai...
|
|
WO/2020/055672A1 |
Provided herein are compounds of the Formula (I): (I) and tautomers, stereoisomers and pharmaceutically acceptable salts and solvates thereof, wherein Rx, Ry, W, X, Y, Z, Ring A and (AA) have the meanings given in the specification, whic...
|
|
WO/2020/054657A1 |
To provide a compound for selectively inhibiting Nav1.7 rather than Nav1.5. A heteroaromatic amide derivative or a salt thereof which is highly effective for pain and various other Nav1.7-related diseases, the heteroaromatic amide deriva...
|
|
WO/2020/054670A1 |
To provide a compound for selectively inhibiting Nav1.7 rather than Nav1.5. A heteroaromatic amide derivative or a salt thereof which is highly effective for pain and various other Nav1.7-related diseases, the heteroaromatic amide deriva...
|
|
WO/2020/055113A1 |
The present disclosure relates to an organic electroluminescent compound represented by formula 1 and an organic electroluminescent device comprising the same. By comprising the organic electroluminescent compound of the present disclosu...
|
|
WO/2020/048548A1 |
Disclosed are a series of tricyclic compounds, and use thereof in the preparation of medicaments for treating diseases related to CRBN proteins. In particular, disclosed are derivative compounds represented by formula (I) or pharmaceutic...
|
|
WO/2020/048904A1 |
The invention provides new bicyclic heteroaryl compounds having the general formula (I) wherein R1, Ar, n and m are as described herein, compositions including the compounds, processes of manufacturing the compounds and methods of using ...
|
|
WO/2020/048826A1 |
The present invention covers 5-substituted 1-oxa-3,9-diazaspiro[5.5]undecan-2-one compounds of general formula (I) and general formula (I-a), in which R1, R2, R3 and R4 are as defined herein, methods of preparing said compounds, intermed...
|
|
WO/2020/050546A1 |
The present invention provides a compound represented by formula 1, an organic electric element comprising a first electrode, a second electrode, and an organic material layer between the first electrode and the second electrode, and an ...
|
|
WO/2020/050409A1 |
Provided is a novel heterocyclic compound having an aryl hydrocarbon receptor antagonist activity and useful for the promotion of platelet production, the compound being represented by the general formula [I]: wherein ring A, ring B, R1,...
|
|
WO/2020/047241A1 |
The disclosure provides new transdermal pharmaceutical compositions comprising 1-(4-fluoro-phenyl)-4-((6bR,10aS)-3-methyl-2,3,6b,9,10,10a-h
exahydro-1H,7H-pyrido[3',4':4,5]pyrrolo[1,2,3-de]quinoxalin-
8-yl)-butan-1-one or 1-(4-fluoro-phe...
|
|
WO/2020/038387A1 |
A compound of formula (I) and a pharmaceutical composition thereof, and a method for using the compound of formula (I) for the prevention and/or treatment of immune-related diseases. (I)
|
|
WO/2020/041405A1 |
The disclosure includes compounds of Formula (A), (A) wherein R1, R2, R3, R4, R5, R6, R7, R8, R9, R10, and R11, h, j, m, n, k, v, s, g, V, W, L, Z1, Q1, Q2, Q3, Q4, Q5, Q6, and Q7, are defined herein. Also disclosed is a method for treat...
|
|
WO/2020/041406A1 |
The disclosure includes compounds of Formula (A), (A) wherein R1, R2, R3, R4, R5, R6, R7, R8, R9, R10, and R11, h, j, m, n, k, v, s, g, V, W, L, Z1, Q1, Q2, Q3, Q4, Q5, Q6, and Q7, are defined herein. Also disclosed is a method for treat...
|
|
WO/2020/036946A1 |
Provided are compounds of Formula (I'), including compounds of Formulas (I), (II), (III), (IIIA) and (IIIB), wherein L, R1, R3 and n are as defined herein, and pharmaceutically acceptable salts thereof, and methods for their use and prod...
|
|
WO/2020/035425A1 |
The invention provides new heterocyclic compounds having the general formula (I) wherein A, L, X, m, n, R1 and R2 are as described herein, compositions including the compounds, processes of manufacturing the compounds, methods of using t...
|
|
WO/2020/035424A1 |
The invention provides new heterocyclic compounds having the general formula (I) wherein A, L, X, m, n, R1 and R2 are as described herein, compositions including the compounds, processes of manufacturing the compounds and methods of usin...
|
|
WO/2020/030925A1 |
The application relates to heterocyclic urea derivatives and their use in the treatment and prophylaxis of cancer, and to compositions containing said derivatives and processes for their preparation.
|
|
WO/2020/020267A1 |
The present invention provides a deutero-substituted polycyclic pyridone compound and a prodrug thereof, and a composition containing the compound, and use thereof. The deutero-substituted polycyclic pyridone compound is a compound repre...
|
|
WO/2020/022237A1 |
The present invention relates to a therapeutic agent for neuropsychiatric disorders containing a compound represented by formula (1) or a pharmaceutically acceptable salt thereof an active ingredient.
|
|
WO/2020/021252A1 |
Novel compounds of formulae (l)-(lll) are provided, as well as pharmaceutical compositions comprising the novel compounds. Also described are therapeutic uses of the novel compounds, in particular in relation to the treatment of infectio...
|
|
WO/2020/020377A1 |
A compound represented by formula I or a pharmaceutically acceptable salt thereof and a use thereof in preparing a drug for treating, stopping, or preventing a disease or disorder mediated by FGFR4 activity.
|
|
WO/2020/020800A1 |
The present invention relates to compounds of formula (I), wherein R1 to R4 are as described herein, and their pharmaceutically acceptable salt, enantiomer or diastereomer thereof, and compositions including the compounds and methods of ...
|
|
WO/2020/023551A1 |
Naphthyridine compounds of formula (I): variations thereof, and their use as inhibitors of HPK1 (hematopoietic kinase 1) are described. The compounds are useful in treating HPK1-dependent disorders and enhancing an immune response. Also ...
|
|
WO/2020/023560A1 |
Isoquinoline compounds of formula (I) variations thereof, and their use as inhibitors of HPK1 (hematopoietic kinase 1) are described. The compounds are useful in treating HPK1-dependent disorders and enhancing an immune response. Also de...
|
|
WO/2020/018970A1 |
The present disclosure relates to novel sulfonylurea compounds and related compounds useful in treating a disorder responsive to modulation of cytokines such as IL-1β and IL-18, modulation of NLRP3 or inhibition of the activation of NLR...
|
|
WO/2020/016710A1 |
The present invention provides, in part, a compound selected from the group consisting of: 1,1,1,3,3,3-hexafluoropropan-2-yl (3R)-3-{[(cyclopropylmethyl)sulfonyl]amino}-1-oxa-8-azaspiro
[4.5]decane-8-carboxylate; 1,1,1,3,3,3-hexafluoropr...
|
|
WO/2020/017624A1 |
To provide an anticancer agent comprising, as an active ingredient, a derivative that has a tumor proliferation inhibitory effect equivalent to or exceeding that of telomestatin, can be synthesized on a mass scale and has a high chemical...
|
|
WO/2020/018975A1 |
The present disclosure relates to novel sulfonimidamide compounds and related compounds and their use in treating a disorder responsive to modulation of cytokines such as IL-1β and IL-18, modulation of NLRP3 or inhibition of the activat...
|
|
WO/2020/017569A1 |
The purpose of the present invention is to provide a novel T-type calcium channel blocker. A compound represented by general formula (I), a tautomer or stereoisomer of the compound, a pharmaceutically acceptable salt thereof or a solvate...
|
|
WO/2020/012408A2 |
The present invention relates to a process for purification of protected polycyclic carbamoylpyridone derivatives and its conversion to polycyclic carbamoylpyridone derivatives or its pharmaceutically acceptable salts thereof.
|
|
WO/2020/009374A1 |
The present invention relates to a 4-substituted oxazoloquinolinone derivative, and a compound, which is a salt of the derivative, that show effects of preventing and treating allergic diseases, such as asthma or atopic dermatitis, by co...
|
|
WO/2020/009179A1 |
The present invention provides a compound which has an effect of inhibiting amyloid β production, especially an effect of inhibiting BACE1, and which is useful as a therapeutic or prophylactic agent for diseases induced by production, s...
|
|
WO/2020/007219A1 |
Disclosed in the present invention are a crystalline form of an EGFR inhibitor and a preparation method therefor, and further comprised is an application of the crystalline form in preparing a drug for treating non-small cell lung cancer.
|
|
WO/2020/008317A1 |
The present invention is directed to acylsulfonamide derivatives of formula (I), pharmaceutical compositions containing them and their use as antagonists of the EP3 receptor, for the treatment of, for example, impaired oral glucose toler...
|
|
WO/2020/004594A1 |
This prophylactic or therapeutic agent for spinal muscular atrophy includes a compound represented by formula (I) or a salt thereof (in the formula: W1, W2, and W3 are each independently selected from the group consisting of C-R2, C-R3, ...
|
|
WO/2020/003151A1 |
The present invention relates to process for the preparation of sodium (2R,5S,13aR)-7,9-dioxo-10-((2,4,6-trifluorobenzyl)carbamoyl)
-2,3,4,5,7,9,13,13a-octahydro-2,5-methanopyrido [1',2':4,5] pyrazino[2,1-b] [1,3] oxazepin-8-olate of For...
|
|
WO/2020/005887A1 |
Provided are compounds of Formula (I) or a pharmaceutically acceptable salt thereof, wherein X, R1, R2, and R3 are as defined herein. Also provided is a pharmaceutically acceptable composition comprising a compound of Formula (I), or a p...
|
|
WO/2020/001420A1 |
Provided by the present application are a cell necrosis inhibitor, a preparation method therefor and a use thereof; in particular, provided by the present application is an inhibitor of cell necrosis and/or human receptor-interacting pro...
|
|
WO/2020/001415A1 |
The present invention relates to a compound, a pharmaceutical composition containing the compound, and a preparation method therefor, and the use of same as a TRK inhibitor. The compound is a compound as shown in formula I, or a pharmace...
|
